Browsing by Author "Ersoy, Ozgur"

Now showing 1 - 17 of 17

Decompression of Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Support as a Step to Transplant
(2016) Gultekin, Bahadir; Ersoy, Ozgur; Akkaya, Ilknur; Kayipmaz, Cagri; Pirat, Aras; Sezgin, Atilla; 27805509; ABA-7388-2021
Objectives: Left ventricular distention can be recognized during the use of venoarterial extracorporeal membrane oxygenation as a key complication. Left ventricular decompression may decrease pulmonary pressure, minimize ventricular distention, and allow myocardial recovery. Materials and Methods: We applied venoarterial extracorporeal membrane oxygenation to 4 patients while on a wait list for cardiac transplant. Results: Two patients with severe heart failure developed high end-diastolic pressures leading to left ventricular distention. We used atrial venting methods to decrease the pressure. Conclusions: Here, we discussed the strategies to manage ventricular distention by conservative, interventional, and surgical means.
Effect of Left Ventricular Assist Devices on Red Blood Cell Distribution Width
(2015) Ersoy, Ozgur; Gultekin, Bahadir; Ozkan, Murat; Akkaya, Ilknur; Umaroglu, Sevi; Sezgin, Atilla; 26640934; ABA-7388-2021
Objectives: Red blood cell distribution width is a measure of the variability in the size of circulating erythrocytes, which is calculated by automated blood cell counters as part of a routine blood cell count analysis. Our aim was to examine whether continuous flow left ventricular assist devices affected red blood cell distribution width. Materials and Methods: Our study included 16 of 24 patients who received a HeartWare HVAD Pump (HeartWare Inc, Framingham, MA, USA) implant (continuous flow left ventricular assist device) between April 2012 and February 2015 at our institution. The mean age of the patients was 46.6 years. We compared patient erythrocyte, leucocyte, and platelet counts, hemoglobin and hematocrit levels, mean corpuscular volume, and red blood cell distribution width values before and 6 months after implant. Results: Hemoglobin level (P=.008), hematocrit level (P=.027), and mean corpuscular volume (P=.003) were significantly decreased; however, we observed no significant change in red blood cell distribution width. Conclusions: Although we did not find significant results in our group of patients with left ventricular assist device implant, a larger group of patients may show more significant results, and an increase in red blood cell distribution width can be used as an indicator of a negative prognosis in these patients.
HLA Sensitization in End-Stage Heart Failure Patients Supported By Extracorporeal Membrane Oxygenation
(2018) Aliyev, Anar; Ersoy, Ozgur; Gultekin, Bahadir; Beyazpinar, Sarp; Basturk, Bilkay; Sezgin, Atilla; Aslamaci, Sait; 0000-0002-8784-1974; ABA-7388-2021; AAD-6918-2021
Impact of Renal Injury on Survival Following Left Ventricular Assist Device
(2018) Beyazpinar, Sarp; Ersoy, Ozgur; Gultekin, Bahadir; Sezgin, Atilla; Aslamaci, Sait; ABA-7388-2021
Incidence and Outcomes of Acute Kidney Injury After Orthotopic Cardiac Transplant: A Population-Based Cohort
(2015) Gultekin, Bahadir; Beyazpinar, Deniz Sarp; Ersoy, Ozgur; Ozkan, Murat; Akay, Hakki Tankut; Sezgin, Atilla; 26640905; ABA-7388-2021; ABA-9675-2021
Left Ventricular Assist Device Management Strategy
(2018) Ersoy, Ozgur; Gultekin, Bahadir; Beyazpinar, Sarp; Sade, Elif; Sezgin, Atilla; Aslamaci, Sait; ABA-7388-2021
Left Ventricular Assist Device Results: Single Center Experience
(2015) Gultekin, Bahadir; Ersoy, Ozgur; Ozkan, Murat; Akkaya, Ilknur; Umaroglu, Sevi; Sezgin, Atilla; 26640938; ABA-7388-2021
Objectives: The number of patients with end-stage cardiac failure who are waiting for transplant has been increasing, although number of heart donations stays limited. This has resulted in an increased use of left ventricular assist devices. Here, we present results of patients who received left ventricular assist device implants at Baskent University Ankara Hospital. Materials and Methods: We retrospectively evaluated 24 patients who received a HeartWare left ventricular assist device (HeartWare Inc, Framingham, MA, USA) between April 2012 and February 2015; 2 patients (8.33%) were female. Results: Patients had end-stage heart failure as a result of the following causes: 11 patients (45%) had ischemic cardiomyopathy, 12 patients (50%) had dilated cardiomyopathy, and 1 patient (4.1%) had acute myocarditis. Regarding use of the left ventricular assist device, 10 patients (41.6%) had the device as destination therapy, and the remaining 14 patients (48.6%) had it as bridge to transplant. The Interagency Registry for Mechanically Assisted Circulatory Support Profile was 1 for 3 patients (12.5%), 2 for 9 patients (37.5%), and 3 for 12 patients (50%). Mean follow-up was 239.8 days, and the mortality rate was 33.3% (8 patients died). During follow-up, we found that 3 patients (12.5%) had received a heart transplant and 1 patient (4.1%) eventually recovered, with the device extracted. Six patients had driveline infections, and 3 patients had cerebrovascular events. Conclusions: With the insufficient number of cardiac donors, use of a left ventricular assist device for patients with end-stage cardiac failure who are awaiting transplant may be the best option.
Low Molecular Weight Heparine As Alternative Anticoagulation Therapy in Patients with Left Ventricular Assist Devices
(2016) Ersoy, Ozgur; Gultekin, Bahadir; Kutllovci, Arber; Akkaya, Ilknur; Akay, H. Tankut; Sezgin, Atilla; ABA-7388-2021
Neurologic Complications in Heart Transplant Recipients Readmitted to the Intensive Care Unit
(2021) Sahinturk, Helin; Yurtsever, Beyza Meltem; Ersoy, Ozgur; Kibaroglu, Seda; Zeyneoglu, Pinar; 34926017
Introduction Neurologic complications after transplantation surgery are major causes of morbidity, and the incidence of neurologic complications among heart transplant recipients varies from 7% to 81%. In our study, we aimed to determine the incidence, etiologies, and risk factors of neurologic complications among patients readmitted to the intensive care unit (ICU) after heart transplantation. Method In this retrospective cohort study, the medical records of all patients who underwent cardiac transplantation from February 2003 to July 2019 were reviewed, and those admitted to the ICU due to neurologic complications during the early and late postoperative period were evaluated. The patients were divided into two groups based on the development of neurologic complications to compare demographic and other characteristics. Results A total of 130 heart transplant recipients were analyzed. We excluded 33 patients from the study because they either had neurologic complications or died postoperatively without discharge from the intensive care unit. The mean age of the cohort was 35.4 +/- 18.5 years, and 74 (76.3%) were male. Out of those 97 heart transplant recipients, 22 (22.7%) developed neurologic complications. Five patients (22.7% ) were admitted to the ICU in the first month, six patients (27.3%) were admitted to the ICU between one and six months, and 11 patients (50%) were admitted to the ICU six months after transplantation due to neurologic complications. The most common diagnosis was posterior reversible encephalopathy syndrome (PRES) (n = 6, 27.3%). The other diagnoses were calcineurin inhibitor toxicity (n = 5, 22.7%), intracranial hemorrhage (n = 3, 13.6%), seizures (n = 2, 9.2%), stroke (n = 2, 9.2%), femoral neuropathy (n = 1, 4.5%), myopathy (n = 1, 4.5%), phrenic nerve damage (n = 1, 4.5%), and cerebral abscess (n = 1, 4.5%). The rate of neurologic complications was higher in males when compared with females (p = 0.03). Both groups were similar in terms of the etiologies of cardiac failure, coexisting disease, and anticoagulant and immunosuppressive usage. The requirement for mechanical ventilation, renal replacement therapy, and the incidence of acute kidney injury were similar in both groups (p > 0.05). The incidence of sepsis was significantly higher in patients with neurologic complications (n = 8, 36.4%, versus n = 5, 6.7%; p < 0.001). The mean length of hospital stay was significantly higher in patients with neurologic complications (21.4 +/- 15.8 versus 11.1 +/- 13.3 days, p = 0.01). The risk of developing neurologic complications is 3.036 times higher in males, and this is statistically significant (odds ratio (OR), 3.036; 95% confidence interval (CI), 1.078-8.444; p = 0.036). Conclusion Our results suggest that neurologic complications develop in 22.7% of heart transplant recipients admitted to the ICU, and half of them are seen after six months postoperatively. PRES was the most frequent (27.3%) neurologic complication. The risk of neurologic complications is three times higher for males. The mean length of hospital stay and incidence of sepsis were significantly higher in heart transplant recipients who developed neurologic complications.
Posterior Reversible Encephalopathy Syndrome After Pediatric Heart Transplantation
(2018) Orgun, Ali; Erdogan, Ilkay; Varan, Birgul; Tokel, Kursad; Ozkan, Murat; Sezgin, Atilla; Ersoy, Ozgur; Aslamaci, Sait; 0000-0002-6719-8563; 0000-0002-6759-1795; 0000-0001-6887-3033; AAJ-2305-2021; ABB-1767-2021; AAF-3253-2021; ABB-2220-2021
Removal of Left Ventricular Assist Device: First Case from Turkey
(2016) Gultekin, Bahadir; Ozkan, Murat; Ersoy, Ozgur; Varan, Birgul; Sezgin, Atila; 0000-0002-6719-8563; ABA-7388-2021; ABB-1767-2021
In recent years, due to the donor shortage for heart transplantation, the utilization of the left ventricular assist devices has been increasing in Turkey, as well as the worldwide. Herein, we report the first case from Turkey, a 12-year-old male case of left ventricular assist devices due to cardiomyopathy developing after monomorphic atrial tachycardia which was explanted after 109 days follow-up.
Results of Endomiocardial Biopsy in Children with Heart Transplantation
(2018) Erdogan, Ilkay; Orgun, Ali; Varan, Birgul; Tokel, Kursad; Ozkan, Murat; Sezgin, Atilla; Ersoy, Ozgur; Aslamaci, Sait; 0000-0001-6887-3033; 0000-0002-6719-8563; 0000-0002-6759-1795; ABB-2220-2021; ABB-1767-2021; AAF-3253-2021
Successful liver and kidney transplantations from a donor with left ventricular assist device
(2019) Sahinturk, Helin; Kaya, Deniz; Ersoy, Ozgur; Zeyneloglu, Pinar; Haberal, Mehmet
Treatment of Left Ventricular Assist Device Thrombosis: Single-Center Experience
(2018) Beyazpinar, D. Sarp; Ersoy, Ozgur; Gultekin, Bahadir; Aliyev, Anar; Avsever, Mert; Akay, H. Tankut; Ozkan, Murat; Sezgin, Atilla; Aslamaci, Sait; 29528019; ABA-9675-2021; ABA-7388-2021
Heart failure is the one of the biggest health problem in the world. Because of limited donors for heart transplant procedures, the ventricular assist device has become a solution for heart failure therapy. With the increase in number of ventricular assist devices, the incidence of complications has also increased. One of the most important life-threatening complications is ventricular assist device thrombosis. Medical therapy and changes in the ventricular assist device are the main therapy methods for ventricular assist device thrombosis. In this study, we showed our clinical experience with treatment of ventricular assist device thrombosis.
Venoarterial Extracorporeal Membrane Oxygenation Support as a Bridge to Heart Transplant: Report of 3 Cases
(2016) Gedik, Ender; Ulas, Aydin; Ersoy, Ozgur; Atar, Funda; Firat, Aynur Camkiran; Pirat, Arash; 0000-0002-7175-207X; 0000-0002-8130-9901; 0000-0003-1470-7501; 27805530; ABI-2971-2020
Heart transplant is the only definitive treatment of end-stage heart failure. Venoarterial extracorporeal membrane oxygenation may be used as a bridge to heart transplant. Among 31 patients who underwent heart transplant between January 2014 and June 2016, we present our experiences with 3 patients who received venoarterial extracorporeal support as a bridge to heart transplant. The first patient was a 51-year-old male with ischemic dilated cardio myopathy. Transplant was performed after 6 days of extracorporeal support, and the patient was discharged and alive at follow-up. Patient 2 was a 12-year-old girl with dilated cardiomyopathy who presented with cardiac arrest. Extracorporeal support was initiated during cardiopulmonary resuscitation. She had full neurologic recovery and remained on the wait list. She received a transplant 22 days after resuscitation. She survived and was alive at day 220 posttransplant. The third patient was a 50-year-old male with ischemic dilated cardiomyopathy requiring venoarterial extracorporeal support. Percutaneous balloon atrial septostomy was performed for left ventricle venting. He underwent transplant on day 28 after intensive care unit admission. He died 29 days after release from the hospital. Regarding patients on heart transplant wait lists who are worsening despite optimal medical therapy, venoarterial extracorporeal membrane oxygenation support is a safe and viable last resort.
Venoarterial Extracorporeal Membrane Oxygenation Support As A Bridge To Heart Transplantation: Report of Three Cases
(2016) Gedik, Ender; Ulas, Aydin; Ersoy, Ozgur; Atar, Funda; Firat, Aynur Camkiran; Zeyneloglu, Pinar; Sezgin, Atilla; Pirat, Arash; https://orcid.org/0000-0002-7175-207X; ABI-2971-2020
What Should be the Treatment Approach in Patients with Cardiac Allograft Vasculopathy?
(2018) Ersoy, Ozgur; Beyazpinar, Sarp; Gultekin, Bahadir; Sezgin, Atilla; Aslamaci, Sait; ABA-7388-2021